Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market ...

Eli Lilly’s first quarter was a bit better than Wall Street had anticipated, but it wasn’t enough for traders on Thursday ...

Pfizer Inc. is cutting at least another $1.2 billion from its spending while the company searches for its next big hit after ...

Pfizer ( ($PFE) ) has been popular among investors this week. Here is a recap of the key news on this stock. Pfizer (PFE) has been the focus of ...

Merck projects $200 million in tariff costs, boosts U.S. manufacturing plans, and continues M&A efforts amid external pressures and shifting market dynamics.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $58.71, a high ...

Goldman Sachs analyst Asad Haider maintained their bullish stance on the stock, giving it a Buy rating on April 8. The ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the ...

Haider sees this dip as an ideal entry point ... Eli Lilly has received not only a “Buy” rating from Goldman Sachs, but also an overall “Strong Buy” rating on Wall Street.

With a market cap of $717 billion, Eli Lilly (LLY) is one of the world’s largest pharmaceutical companies. Lilly is well-known for its innovative drug pipeline and longstanding presence in the global ...

Goldman Sachs has been deepening its investments in generative artificial intelligence. CEO David Solomon has said the bank's AI tools will "scale and transform our engineering abilities." ...

Lilly's weight-loss drug trial shows promising results, propelling stock up 14.36%. Goldman Sachs predicts potential $23.5B in sales by 2035.